ODI Pharma AB: Publication of interim report for the first quarter 2021/2022
ODI Pharma AB (“ODI Pharma” or the “Company”) hereby publishes its interim report concerning the period July 2021 – September 2021. The report is available as an attached document to this press release and on the Company’s website (www.odipharma.com). Below is a summary of the report.First quarter (2021-07-01 – 2021-09-30) The Group's net sales amounted to SEK 0 (0). The Group's loss after financial items amounted to SEK -1,175,388 (-1,268,107). Result per share amounted to SEK -0.08 (-0.08).* The solidity as of 2021-09-30 was 94 % (97 %).** * The Company’s result per share: